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Metastatic malignancy represents a common cause of effusions.
Immunocytochemistry (ICC) is useful in confirming malignancy
and gaining insight into the site of origin. Cell blocks are com-
monly utilized for this purpose; nonetheless, when the malignant
cells are sparse, they may not be represented in cell blocks
thereby precluding immunophenotypic characterization. Thus, we
sought to investigate the utility of direct smear preparations as a
platform for ICC in the diagnosis of effusions. Air-dried,
unstained direct smears were prepared from 49 malignant effu-
sions and 17 reactive effusions for comparison. ICC for EMA and
MOC-31 highlighted the tumor cells in 91 and 98% of the malig-
nant effusions tested, respectively. EMA immunoreactivity was
focally observed within the calretinin-positive mesothelial cell
population in 1 (6%) of the 17 reactive effusions. ICC for MOC-
31 was negative in all reactive effusions. Site-specific immuno-
markers were also evaluated. Immunoreactivity for Napsin-A and
TTF-1 were observed in 78 and 67% of metastatic lung adenocar-
cinomas, respectively. ICC for PAX8 highlighted metastatic Mu¨l-
lerian and thyroid carcinomas in 100% of cases tested. CDX-2
immunoreactivity was observed in 25, 60, and 100% of metastatic
gastric, pancreatic, and colorectal adenocarcinomas, respec-
tively. Positivity for p63 was observed in 75% of metastatic uro-
thelial cell carcinomas and the one case of pulmonary squamous
cell carcinoma examined. Calretinin ICC highlighted the tumor
cells in both malignant mesothelioma cases tested as well as the
benign mesothelial cells in the reactive effusions. In conclusion,
direct smears represent an effective platform for the performance
of ICC in the diagnosis of malignant effusions. Diagn. Cytopathol.
2013;41:425–430. ' 2012 Wiley Periodicals, Inc.
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Metastatic malignancy is a common cause of fluid accu-
mulation in the pleural, peritoneal, and pericardial spaces.
Of these, metastatic carcinoma represents the most com-
mon etiology of malignant effusions.1 Clinical informa-
tion including the site of effusion, sex of the patient, and
any history of malignancy in addition to knowledge of
commonly encountered malignant effusions can be of aid
to the pathologist during the initial evaluation and accu-
rate diagnosis of an effusion specimen.2,3 Ancillary
immunocytochemistry (ICC) can be employed to confirm
a metastasis from a patient’s already documented primary
malignancy. In addition, for instances in which a malig-
nancy is suspected in an effusion specimen and the pri-
mary site is unknown, immunocytochemistry can serve as
a diagnostically useful adjunct to routine cytomorphologic
evaluation as it can assist in identifying malignant cells
and elucidating possible sites of origin. Accurate and
specific diagnoses of malignant effusions yield important
information regarding the nature and extent of metastatic
disease enabling prompt, appropriate treatment.
In this regard, cell block preparations are commonly
utilized for ancillary immunohistochemical studies. How-
ever, this platform is fraught with a significant limitation;
it is not uncommon for the cells of interest to present
only as a minority population within the milieu of back-
ground mesothelial cells, histiocytes, and other inflamma-
tory cells. For cases in which the malignant cells are
sparse in cytology specimens, the cells of interest may
not be well represented in cell blocks thereby precluding
further characterization via ancillary techniques. As an
illustration, Mulvahy analyzed 75 malignant peritoneal
washing specimens; malignant cells were visualized on
smear preparations in 97% of these cases while they were
seen in the cell block preparations in 51% of cases.4
{Dr. Knoepp and Dr. Placido contributed equally to the work.
Department of Pathology, University of Michigan Medical School,
Ann Arbor, Michigan
*Correspondence to: Michael H. Roh, MD, PhD, 2G332 UH,
Department of Pathology, University of Michigan Health System, 1500
E. Medical Center Drive, Ann Arbor, Michigan 48109, USA.
E-mail: mikro@med.umich.edu
Received 18 November 2011; Accepted 11 February 2012
DOI 10.1002/dc.22852
Published online 30 April 2012 in Wiley Online Library
(wileyonlinelibrary.com).
' 2012 WILEY PERIODICALS, INC. Diagnostic Cytopathology, Vol 41, No 5 425
Furthermore, we and others have observed variations in
tumor cellularity in cell block preparations of lung carci-
noma cytology specimens.5,6 In our previous analysis of
26 lung carcinoma cytology specimens, cell blocks were
acellular in 9 (35%) of these cases.5 Similarly, Swati et
al. observed that 2 (25%) of 8 cell blocks from lung can-
cer aspirates exhibited a percent tumor cellularity of 2%
or less.6
We have previously demonstrated that direct smears
represent a robust platform for the performance of ICC
and molecular testing using cytology specimens. For
instance, we reported the application of ICC for Napsin-
A, TTF-1, and p63 to unstained, air-dried direct smears of
pulmonary non-small cell carcinomas to assist in the sub-
classification of these tumors as adenocarcinoma or squa-
mous cell carcinoma.7 Next, we demonstrated that Diff-
Quik stained direct smears of lung cancers can be suc-
cessfully utilized for tumor cell microdissection, subse-
quent tumor DNA extraction, and molecular testing for
EGFR and KRAS mutations.5 In addition, we extended
our methodology to fine-needle aspirates of metastatic
melanoma. Specifically, unstained air-dried direct smears
were utilized for confirmatory ICC using antibodies
against S100, HMB45, and Melan-A.8 Furthermore, the
effectiveness of Diff-Quik stained direct smears of mela-
noma as a platform for BRAF mutational analysis was
demonstrated in that study. Recently, we reported the
efficacy of ICC for CK20 using direct smears in the diag-
nosis of metastatic Merkel cell carcinoma.9
There are only a limited number of studies in the litera-
ture that address the application of ICC to direct smears
prepared from effusions.10–12 Thus, we sought to further
investigate the applicability of ICC to direct smears pre-
pared from malignant and benign effusion specimens.
Herein, we report our experience with the application of
ICC for EMA and MOC-31 in the diagnosis of malignant
effusions as well as the use of select differentiation- and
site-specific immunomarkers geared towards ascertaining
the site of origin of malignant effusions.
Materials and Methods
The study was approved by the Institutional Review
Board at University of Michigan. Air-dried, unstained
direct smears were prepared using positively charged
slides for 49 malignant effusions. Specifically, 50–100
cm3 of each fluid specimen was centrifuged for 5 min at
2,400 rpm at room temperature. The supernatant was
carefully decanted and the pellet was resuspended in re-
sidual supernatant fluid using a syringe and evenly distrib-
uted onto slides for smear preparation. One smear was
stained with Diff-Quik for cytomorphologic analysis as a
reference for identifying cytologically malignant cells on
the immunostained slides. For each case, the electronic
medical record, including pathology reports and clinical
notes, were examined to identify patients with known
cancer histories.
ICC was performed on air-dried, unstained direct
smears following formalin fixation for 60 min. ICC for
Napsin-A, TTF-1, and p63 were performed as described
previously.7 ICC for EMA (1:100 dilution; DAKO, Car-
penteria, CA), MOC-31 (1:100 dilution; DAKO, Carpen-
teria CA), PAX8 (1:200 dilution; Protein Tech, Chicago,
IL), CDX-2 (predilute; Ventana Medical Systems, Tucson,
AZ), and calretinin (1:100 dilution; Zymed, Carlsbad,
CA) was performed following pretreatment in CC1 buffer
(Ventana Medical Systems, Tucson, AZ). The list of anti-
bodies tested for each category of malignant effusions
based on the type and origin of malignancy is shown in
Table I.
For each antibody, immunocytochemistry performed on
unstained smears prepared from specimens with estab-
lished diagnoses, in which positive immunostaining
Table I. Results of Immunocytochemistry on Direct Smears Prepared
From Malignant Effusions
Primary site (number of cases) Immunostain
No. of positive
(% of cases)




Lung squamous cell carcinoma (n ¼ 1) p63 1 (100%)
Breast adenocarcinoma (n ¼ 4) EMA 4 (100%)
MOC-31 4 (100%)
Gastric adenocarcinoma (n ¼ 4) EMA 3 (75%)
MOC-31 4 (100%)
CDX-2 1 (25%)
Pancreatic adenocarcinoma (n ¼ 5) EMA 3 (60%)
MOC-31 5 (100%)
CDX-2 3 (60%)
Colorectal adenocarcinoma (n ¼ 2) EMA 1 (50%)
MOC-31 2 (100%)
CDX-2 2 (100%)
Mu¨llerian adenocarcinoma (n ¼ 15) EMA 15 (100%)
MOC-31 15 (100%)
PAX8 15 (100%)
Urothelial cell carcinoma (n ¼4) p63 3 (75%)
Malignant mesothelioma (n ¼ 2) EMA 2 (100%)
MOC-31 1 (50%)
Calretinin 2 (100%)
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results were obtained, represented positive controls. Fur-
thermore, immunohistochemistry performed on unstained
sections from tissue microarrays represented an additional
source of positive controls. Negative control immuno-
stains, in which the primary antibody was omitted, were
also performed on unstained direct smears for each case.
Next, air-dried, unstained direct smears were prepared
on positively charged slides for 17 reactive effusions. In
these 17 cases, ICC for all eight antibodies was performed;
this cohort served as a negative control cohort as well.
Results
Of the 49 malignant effusions examined in this study, the
primary site was known in 48 cases (Table I): 10 lung
carcinomas (9 adenocarcinomas and 1 squamous cell car-
cinoma); 4 breast adenocarcinomas; 4 gastric adenocarci-
nomas; 5 pancreatic adenocarcinomas; 2 colorectal adeno-
carcinomas; 15 Mu¨llerian adenocarcinomas; 4 urothelial
cell carcinomas; 2 malignant mesotheliomas; and 2
thyroid carcinomas (1 papillary thyroid carcinoma and 1
anaplastic thyroid carcinoma). In one case of malignancy,
the site of origin was unknown and immunocytochemical
workup failed to identify a definite primary site. This
patient was considered clinically to harbor a tumor of
unknown primary. For comparison, 17 cases of benign,
reactive effusions were also examined in this study.
ICC on direct smears for EMA and MOC-31 were per-
formed for 44 of the 49 malignant effusions (Table I); the
1 case of metastatic pulmonary squamous cell carcinoma
and the 4 cases of metastatic urothelial cell carcinoma
were not examined by ICC for these two markers. Strong,
diffuse immunoreactivity for EMA was observed in the
tumor cells in 91% (40/44) of the cases tested (Fig. 1).
Specifically, 100% of the lung adenocarcinomas (9/9),
breast adenocarcinomas (4/4), Mu¨llerian adenocarcinomas
(15/15), malignant mesotheliomas (2/2), and thyroid carci-
nomas (2/2) were positive for EMA. Furthermore, 75%
(3/4) of gastric adenocarcinomas, 60% (3/5) of pancreatic
adenocarcinomas, and 50% (1/2) of colorectal adenocarci-
nomas exhibited EMA positivity in the tumor cells. The
one adenocarcinoma of unknown primary was positive for
EMA. Next, MOC-31 immunoreactivity in the tumor cells
was observed in 98% (43/44) of the cases tested (Fig. 1).
In 42 of the 43 MOC-31(+) cases, MOC-31 positivity was
strong and diffuse. In one case of malignant mesothe-
lioma, focal (<10% of tumor cells) positivity for MOC-
31 was observed (Fig. 1). Of note, in the one case of gas-
tric adenocarcinoma, two cases of pancreatic adenocarci-
noma, and the one case of colorectal adenocarcinoma in
which the tumor cells were negative for EMA, ICC for
MOC-31 highlighted the tumor cell population. No MOC-
31 immunoreactivity was observed in any of the tumor
cells in one case of malignant mesothelioma.
Next, we examined the use of site-specific immuno-
markers utilizing direct smears of effusions. The results
are summarized in Table I and representative images are
displayed in Figure 2. Immunoreactivity for Napsin-A and
TTF-1 was observed in the tumor cells in 78% (7/9) and
67% (6/9) cases of lung adenocarcinoma, respectively. A
Fig. 1. Immunocytochemistry for EMA and MOC-31 using direct
smears of malignant effusions. Photomicrographs of Diff-Quik stained
smears and immunostains for EMA and MOC-31 for representative cases
of metastatic lung adenocarcinoma, breast adenocarcinoma, pancreatic
adenocarcinoma, colonic adenocarcinoma, Mu¨llerian adenocarcinoma,
papillary thyroid carcinoma, anaplastic thyroid carcinoma, and malignant
mesothelioma are displayed (31,000).[Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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granular cytoplasmic staining pattern for Napsin-A and
distinct nuclear immunopositivity for TTF-1 was
observed. Nuclear immunoreactivity for CDX-2 was
observed in 25% (1/4) of gastric adenocarcinomas, 60%
(3/5) of pancreatic adenocarcinomas, and 100% (2/2) of
colorectal adenocarcinomas. ICC for PAX8 highlighted
the nuclei of the tumor cells in 100% (15/15) of Mu¨ller-
ian adenocarcinomas and 100% (2/2) of thyroid carcino-
mas. Nuclear immunoreactivity for p63 was observed in
the one case of pulmonary squamous cell carcinoma and
75% (3/4) of urothelial cell carcinomas. Nuclear and cyto-
plasmic immunoreactivity for calretinin was observed in
100% (2/2) of cases of malignant mesothelioma, confirm-
ing mesothelial differentiation. In the one adenocarcinoma
of unknown primary, none of the site-specific markers
tested (Table I) were positive. For the above cases, the
negative control immunostains, in which the primary anti-
body was omitted, were negative confirming the specific
staining patterns observed for each antibody.
A total of 17 benign, reactive effusions were also tested
for comparison. Calretinin positivity was observed in the
mesothelial cell population in all cases. Focal EMA posi-
tivity (<10%) was observed in the mesothelial cells in
6% (1/17) of reactive effusions. Immunostains for MOC-
31, Napsin-A, TTF-1, CDX-2, PAX8, and p63 were nega-
tive in all 17 cases of benign effusions.
Discussion
Traditionally, cell blocks are utilized for immunopheno-
typing tumor cells in malignant effusions. Nonetheless,
paucicellularity of the tumor cell population and, conse-
quently, underrepresentation of tumor cells in cell block
preparations represents a significant limitation.4–8
Employing direct smears as a platform for immunocyto-
chemistry is advantageous in several respects. First, multi-
ple unstained direct smears can be prepared from pelleted
cellular material. One of the smears can be rapidly stained
via the Diff-Quik staining protocol and immediately
assessed for the presence or absence of tumor cells as
well as percent tumor cellularity. Second, the tumor cellu-
larity in cell block preparations is not immediately
known. Instead, the composition of cell blocks can only
be ascertained after processing of the cell blocks and sub-
sequent preparation of H&E slides by histotechnologists.
This leads to a relative increase in turnaround time for
rendering an accurate, specific diagnosis encompassing
requisite immunostains. In contrast, unstained, air-dried
direct smears can be rapidly prepared, immediately sub-
mitted for immunocytochemistry without the need for
interim processing steps, and the immunostained slides can
be obtained within hours. Third, the cytomorphology of the
tumor cells on the immunostains are preserved facilitating
direct correlation with Diff-Quik stained smears.
Fig. 2. Immunocytochemistry for site-specific markers using direct smears of malignant effusions. Representative immunostains for TTF-1, Napsin-A,
CDX-2, PAX8, calretinin, and p63 are shown as indicated in each photomicrograph (31,000). Abbreviations: ADC, adenocarcinoma; SQC, squamous
cell carcinoma; PTC, papillary thyroid carcinoma; ATC, anaplastic thyroid carcinoma. [Color figure can be viewed in the online issue, which is avail-
able at wileyonlinelibrary.com.]
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There currently exist a limited number of studies exam-
ining the use of a panel of immunocytochemical stains to
direct smears prepared from effusions.10–12 Herein, we
report our experience in applying ICC to direct smear
preparations of effusion specimens. Our study augments
the current knowledge about this topic in several respects.
Similar to our study, Ueda et al. examined ICC using
antibodies directed against EMA and MOC-3112; we
observed that EMA and MOC-31 were highly sensitive in
detecting malignant cells consistent with their findings. In
contrast to their study, we also examined the use of addi-
tional markers that are specific to particular primary sites
of origin. Similar to Pomjanski et al.,10 we investigated
the application of ICC for the site-specific markers, TTF-
1 and CDX-2 to direct smears. Furthermore, we extended
our analysis to investigating additional site-specific
markers, specifically PAX8, Napsin-A, and p63. Our anal-
ysis also differs from the two aforementioned studies with
respect to the nature of direct smear preparations used.
Ueda et al and Pomjanski et al. examined smears fixed in
ethanol and Delaunay’s fixative (500 mL 100% alcohol,
500 mL acetone, and 10 drops of 1M trichlorvinegar
acid). On the other hand, we applied ICC to air-dried
smears fixed in formalin. These fixation conditions reca-
pitulate those used on histologic sections prepared from
formalin-fixed tissue blocks and we have reported the suc-
cessful implementation of this methodology in prior
reports.7–9
Our findings support the effectiveness of utilizing
immunocytochemical stains for EMA and MOC-31 in the
diagnosis of malignant effusions. ICC for EMA and
MOC-31 highlighted the tumor cells in 91 and 98% of
malignant effusions tested, respectively. In contrast, the
immunostains for EMA and MOC-31 were negative in 94
and 100% of the benign, reactive effusions tested. This
high level of sensitivity and specificity are concordant
with the results of previous studies that evaluated these
two markers in the diagnosis of effusions.13–16 Of note,
both cases of malignant mesothelioma examined in our
study exhibited EMA and calretinin positivity reinforcing
the conclusion from other studies that these two markers
can be utilized in the diagnosis of malignant mesothe-
lioma in effusions.13,16–19 On the direct smear prepara-
tions, the EMA immunostain appeared to highlight the
malignant mesothelioma cell population in a diffuse cyto-
plasmic pattern (Fig. 1). It should be noted that this stain-
ing pattern can be observed in the context of plasma
membrane staining as entire, intact cells rather than cross-
sections of cells are being examined on immunostains of
direct smears. In support of this, thick membranous im-
munoreactivity for EMA in the malignant cells was
observed on the immunohistochemical stains performed
on the corresponding cell block sections for both cases
(not shown).
In addition, we examined the application of ICC for a
panel of site-specific markers to direct smears prepared
from effusions. First, immunoreactivity for Napsin-A and
TTF-1 was observed in 78 and 67% of pulmonary adeno-
carcinomas. These results recapitulate the findings of two
prior studies that demonstrated the increased sensitivity of
ICC for Napsin-A, compared to TTF-1, in the detection
of metastatic lung adenocarcinoma in effusion speci-
mens.20,21 Second, we observed that PAX8 was highly
effective in detecting metastatic carcinomas of Mu¨llerian
and thyroid origin, consistent with the findings of prior
studies.22–24 Specifically, PAX8 immunoreactivity was
seen in the tumor cells in all Mu¨llerian and thyroid carci-
nomas examined. Interestingly, the one case of metastatic
anaplastic thyroid carcinoma examined in our study
exhibited a TTF-1(-)/PAX8(+) immunophenotype. This is
in line with the findings of Nonaka et al. and Bishop et
al. which demonstrated the increased sensitivity of ICC
for PAX8, compared to TTF-1, in the detection of ana-
plastic thyroid carcinoma.25,26 Third, p63 is expressed in
a high proportion of squamous cell carcinomas as well as
urothelial cell carcinomas.7,27 Accordingly, in this study,
we observed p63 expression in metastatic squamous cell
carcinoma (1/1; 100%) and urothelial cell carcinoma (3/4;
75%) in effusions. Finally, we observed CDX-2 immuno-
reactivity in 25, 60, and 100% of metastatic gastric, pan-
creatic, and colorectal adenocarcinomas, respectively.
These rates of CDX-2 positivity in these cancers are
concordant with those reported in previously published
series.10,28
In conclusion, we have demonstrated that direct smear
preparations of effusions represent a robust source of
cellular material and an effective platform for ICC. Appro-
priate panels of immunostains can be rapidly applied, in
this setting, to facilitate the identification of metastatic
tumor cells in malignant effusions as well as the confirma-
tion and determination of the primary sites of origin.
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